Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00322374
Status:
COMPLETED
Last Update Posted:
2016-03-10
First Post:
2006-05-01
Brief Title:
Phase I Combination w Epirubicin
Sponsor:
R-Pharm
Organization:
R-Pharm
Study Overview
Official Title:
A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tumor response information was obtained for all participants who received at least 2 cycles of study drug underwent requisite baseline and on-treatment disease assessments and had at least one post-treatment assessment Tumor response assessment in evaluable participants was done according to the Response Evaluation Criteria in Solid Tumors RECIST criteria
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract No 2005-004864-22 | None | None | None |